#1 Clinical Trials Search in Europe

Tipapkinogene Sovacivec

This article provides an overview of a clinical trial investigating the combination of TG4001 (Tipapkinogene Sovacivec) and Avelumab in patients with advanced HPV-16 positive cancers. The study aims to assess the safety, tolerability, and effectiveness of this combination therapy in treating various types of recurrent or metastatic HPV-16 positive malignancies, including head and neck, cervical, vulvar, vaginal, penile, and anal cancers.

Table of Contents

What is Tipapkinogene Sovacivec?

Tipapkinogene Sovacivec, also known as TG4001 or MVATG8042, is an innovative cancer immunotherapy drug developed by Transgene SA[1]. It is classified as a recombinant viral-based immunotherapy, which means it uses a modified virus to stimulate the immune system to fight cancer[1].

How Does It Work?

TG4001 works in a unique way to combat cancer:

  1. It is made from a weakened form of the Vaccinia virus (MVA), which has been genetically modified[1].
  2. This modified virus contains genes that produce non-cancerous versions of the HPV16 proteins E6 and E7, as well as a human protein called interleukin-2 (IL-2)[1].
  3. When injected into the body, it helps the immune system recognize and attack cancer cells that contain these HPV16 proteins.
  4. The added IL-2 helps to boost the overall immune response.

This approach is designed to specifically target cancers caused by the human papillomavirus type 16 (HPV-16), which is responsible for many cases of certain types of cancer[1].

Target Conditions

TG4001 is being studied for the treatment of several HPV-16 positive recurrent or metastatic cancers, including[1]:

  • Oropharyngeal squamous cell carcinoma of the head and neck (a type of throat cancer)
  • Cervical cancer
  • Vulvar cancer
  • Vaginal cancer
  • Penile cancer
  • Anal cancer

These are all cancers that can be caused by persistent HPV-16 infection and have limited treatment options when they become advanced or spread to other parts of the body (metastatic)[1].

Clinical Trial Overview

A clinical trial is currently underway to evaluate the effectiveness and safety of TG4001 in combination with another immunotherapy drug called avelumab[1]. This trial is divided into three parts:

  1. Phase Ib: This initial phase aims to assess the safety and tolerability of combining TG4001 with avelumab[1].
  2. Phase II Part 1: This phase will evaluate how well the combination works in terms of overall response rate (ORR), which measures how many patients’ tumors shrink or disappear[1].
  3. Phase II Part 2: This phase will compare the progression-free survival (PFS) of patients receiving TG4001 plus avelumab versus those receiving avelumab alone[1].

Potential Benefits

The researchers are hoping to see several potential benefits from this treatment combination, including[1]:

  • Improved overall response rate (more patients experiencing tumor shrinkage)
  • Longer progression-free survival (more time before the cancer starts growing again)
  • Improved overall survival
  • Longer duration of response (how long the treatment keeps working)
  • Better disease control rate

Eligibility Criteria

To participate in this clinical trial, patients must meet certain criteria, including[1]:

  • Be at least 18 years old
  • Have a confirmed HPV-16 positive cancer that has either spread or come back after previous treatment
  • Have at least one measurable tumor
  • Have adequate organ function
  • Not have received certain types of immunotherapy before

There are also several conditions that would prevent a person from participating, such as having certain autoimmune diseases or active infections[1].

Safety Considerations

As with any experimental treatment, there are potential risks and side effects to consider. The clinical trial is designed to carefully monitor patients for any adverse reactions. Some important safety considerations include[1]:

  • Patients with a history of certain lung conditions, autoimmune diseases, or severe allergic reactions may not be eligible.
  • The treatment may affect the immune system, so patients with active infections or those taking immunosuppressive drugs may be excluded.
  • Patients with certain heart conditions or uncontrolled diabetes may not be able to participate.

It’s important to note that this treatment is still being studied, and its full safety profile and effectiveness are not yet fully known. Patients considering this or any experimental treatment should discuss the potential risks and benefits thoroughly with their healthcare provider[1].

Aspect Details
Study Drug TG4001 (Tipapkinogene Sovacivec) in combination with Avelumab
Target Conditions HPV-16 positive recurrent or metastatic cancers (head and neck, cervical, vulvar, vaginal, penile, anal)
Study Design Phase Ib/II trial with open-label and randomized controlled portions
Primary Objectives Safety, tolerability, overall response rate, progression-free survival
Key Eligibility Criteria Adults with confirmed HPV-16 positive advanced cancers, measurable disease, adequate organ function
Exclusion Criteria Prior cancer immunotherapy, active autoimmune diseases, significant cardiovascular issues, CNS metastases (with exceptions)

FAQ

  • What is TG4001 and how does it work? TG4001 is a recombinant viral-based immunotherapy. It contains a modified vaccinia virus with genetic sequences for HPV16 proteins E6 and E7 (in non-oncogenic forms) and human interleukin-2. This combination helps stimulate the immune system to target HPV-16 positive cancer cells.
  • What types of cancers are being studied in this trial? The trial focuses on HPV-16 positive recurrent or metastatic cancers, including oropharyngeal squamous cell carcinoma of the head and neck, cervical cancer, vulvar cancer, vaginal cancer, penile cancer, and anal cancer.
  • Who is eligible to participate in this clinical trial? Eligible participants are adults (18 years or older) with confirmed HPV-16 positive advanced cancers that are not suitable for curative treatment. They must have measurable disease and adequate organ function. Specific eligibility criteria vary for different phases of the trial.
  • What are the main objectives of the trial? The main objectives include evaluating the safety and tolerability of the TG4001 and Avelumab combination, assessing the overall response rate, and comparing progression-free survival between the combination therapy and Avelumab alone in patients without liver metastases.
  • How is the trial structured? The trial is divided into three parts: a Phase Ib open-label portion, a Phase II open-label single-arm portion, and a Phase II randomized, controlled two-arm portion comparing the combination therapy to Avelumab alone.

Ongoing Clinical Trials on Tipapkinogene Sovacivec

  • Study of TG4001 and Avelumab for Patients with Advanced HPV-16 Positive Cancers

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Spain

Glossary

  • HPV-16: Human Papillomavirus type 16, a high-risk strain of HPV known to cause various types of cancer, including cervical, anal, and head and neck cancers.
  • Recurrent cancer: Cancer that has returned after a period of time during which it could not be detected.
  • Metastatic cancer: Cancer that has spread from its original site to other parts of the body.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors version 1.1, a standard way to measure how well a cancer patient responds to treatment.
  • Overall Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it getting worse.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Duration of Response (DoR): The length of time that a tumor continues to respond to treatment without growing or spreading.
  • Immunotherapy: A type of cancer treatment that helps the immune system fight cancer.
  • Avelumab: An immunotherapy drug that works by blocking a protein called PD-L1, which helps the immune system attack cancer cells.

References

  1. http://clinicaltrials.eu/trial/study-of-tg4001-and-avelumab-for-patients-with-advanced-hpv-16-positive-cancers/